Cargando…
Angiogenesis in Cancer
New growth in the vascular network is important since the proliferation, as well as metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form through processes called angiogenesis and lymphangiogen...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993983/ https://www.ncbi.nlm.nih.gov/pubmed/17326328 |
_version_ | 1782135461377998848 |
---|---|
author | Nishida, Naoyo Yano, Hirohisa Nishida, Takashi Kamura, Toshiharu Kojiro, Masamichi |
author_facet | Nishida, Naoyo Yano, Hirohisa Nishida, Takashi Kamura, Toshiharu Kojiro, Masamichi |
author_sort | Nishida, Naoyo |
collection | PubMed |
description | New growth in the vascular network is important since the proliferation, as well as metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form through processes called angiogenesis and lymphangiogenesis, respectively. Angiogenesis is regulated by both activator and inhibitor molecules. More than a dozen different proteins have been identified as angiogenic activators and inhibitors. Levels of expression of angiogenic factors reflect the aggressiveness of tumor cells. The discovery of angiogenic inhibitors should help to reduce both morbidity and mortality from carcinomas. Thousands of patients have received antiangiogenic therapy to date. Despite their theoretical efficacy, antiangiogeic treatments have not proved beneficial in terms of long-term survival. There is an urgent need for a new comprehensive treatment strategy combining antiangiogenic agents with conventional cytoreductive treatments in the control of cancer. |
format | Text |
id | pubmed-1993983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-19939832008-03-06 Angiogenesis in Cancer Nishida, Naoyo Yano, Hirohisa Nishida, Takashi Kamura, Toshiharu Kojiro, Masamichi Vasc Health Risk Manag Review New growth in the vascular network is important since the proliferation, as well as metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form through processes called angiogenesis and lymphangiogenesis, respectively. Angiogenesis is regulated by both activator and inhibitor molecules. More than a dozen different proteins have been identified as angiogenic activators and inhibitors. Levels of expression of angiogenic factors reflect the aggressiveness of tumor cells. The discovery of angiogenic inhibitors should help to reduce both morbidity and mortality from carcinomas. Thousands of patients have received antiangiogenic therapy to date. Despite their theoretical efficacy, antiangiogeic treatments have not proved beneficial in terms of long-term survival. There is an urgent need for a new comprehensive treatment strategy combining antiangiogenic agents with conventional cytoreductive treatments in the control of cancer. Dove Medical Press 2006-09 2006-09 /pmc/articles/PMC1993983/ /pubmed/17326328 Text en © 2006 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Nishida, Naoyo Yano, Hirohisa Nishida, Takashi Kamura, Toshiharu Kojiro, Masamichi Angiogenesis in Cancer |
title | Angiogenesis in Cancer |
title_full | Angiogenesis in Cancer |
title_fullStr | Angiogenesis in Cancer |
title_full_unstemmed | Angiogenesis in Cancer |
title_short | Angiogenesis in Cancer |
title_sort | angiogenesis in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993983/ https://www.ncbi.nlm.nih.gov/pubmed/17326328 |
work_keys_str_mv | AT nishidanaoyo angiogenesisincancer AT yanohirohisa angiogenesisincancer AT nishidatakashi angiogenesisincancer AT kamuratoshiharu angiogenesisincancer AT kojiromasamichi angiogenesisincancer |